Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapyDaiki Murata, Tomoaki Hoshino|Cancer Immunology Immunotherapy|2024Cited by 9